Literature DB >> 19020737

Increased growth factor expression after hepatic and pancreatic resection.

Christoph Justinger1, Christian Schlüter, Vilma Oliviera-Frick, Berit Kopp, Claudia Rubie, Martin K Schilling.   

Abstract

Removal of the primary tumour is suggested to associate with an enhanced tumour growth of residual micrometastases. Recent data focus on growth factors that may be released in response to surgery-stimulating receptors of residual tumour cells. Vascular endothelial (VEGF) and hepatocyte growth factor (HGF) are potent inducers of angiogenesis. The two factors are necessary for wound healing and the promotion of tumour growth. This study was designed to determine growth factor serum levels in patients before, during and after major abdominal surgery. It was recently shown that simultaneous hepatic and pancreatic resection led to poor liver regeneration. As growth factors may be involved in these findings we compared the growth factor levels after liver resection with the levels in patients after pancreatic resection. Forty patients were accrued before hepatopancreatic surgery (hepatic resection n=20 and pancreatic resection n=20). Blood samples were taken from each patient immediately prior to surgery, during the operation and on the postoperative days (POD) 1-3, 5 and 10. To examine the wound fluid, liquid from the wound drains was collected on POD 3. Using ELISA the concentration of the angiogenic cytokines HGF and VEGF165 was determined. After the liver and pancreatic resections, circulating HGF and VEGF165 were increased. We found significantly higher levels of HGF on POD 1-3 (p<0.01), compared to preoperative results with a peak on POD 2. After measuring the postoperative VEGF165 levels we found significantly higher levels of circulating VEGF165 on POD 1-5 (p<0.01) compared to the preoperative levels. On comparing liver with pancreatic resection we did not detect significantly different levels of the two growth factors in the two groups. VEGF165 and HGF concentrations measured during the operation demonstrated no change. HGF and VEGF165 levels detected in the wound fluid on POD 3 were approximately 10 times higher than the preoperative serum levels, respectively. In summary, our data show increased VEGF165 and HGF levels after hepatopancreatic surgery. Notably, the lack of an impact of the type of organ resection on the concentration-time curve of the two growth factors suggest that high postoperative growth factor levels are part of normal wound healing and systemic inflammation. Thus, the proangiogenetic potential of growth factors may account for accelerated tumour growth when residual tumour cells are exposed to high levels of VEGF165 and HGF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020737

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer.

Authors:  Shifalika Tangutoori; Bryan Q Spring; Zhiming Mai; Akilan Palanisami; Lawrence B Mensah; Tayyaba Hasan
Journal:  Nanomedicine       Date:  2015-09-25       Impact factor: 5.307

Review 3.  The role of photodynamic therapy in overcoming cancer drug resistance.

Authors:  Bryan Q Spring; Imran Rizvi; Nan Xu; Tayyaba Hasan
Journal:  Photochem Photobiol Sci       Date:  2015-04-09       Impact factor: 3.982

Review 4.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

5.  Influence of cytokines, circulating markers and growth factors on liver regeneration and post-hepatectomy liver failure: a systematic review and meta-analysis.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Omid Ghamarnejad; Mohammedsadegh Nikdad; Pascal Probst; Katrin Hoffmann
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

6.  MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.

Authors:  L D Roy; M Sahraei; D B Subramani; D Besmer; S Nath; T L Tinder; E Bajaj; K Shanmugam; Y Y Lee; S I L Hwang; S J Gendler; P Mukherjee
Journal:  Oncogene       Date:  2010-11-22       Impact factor: 9.867

7.  A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.

Authors:  Bryan Q Spring; R Bryan Sears; Lei Zak Zheng; Zhiming Mai; Reika Watanabe; Margaret E Sherwood; David A Schoenfeld; Brian W Pogue; Stephen P Pereira; Elizabeth Villa; Tayyaba Hasan
Journal:  Nat Nanotechnol       Date:  2016-01-18       Impact factor: 39.213

8.  Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?

Authors:  Inga Bekes; Thomas W P Friedl; Tanja Köhler; Volker Möbus; Wolfgang Janni; Achim Wöckel; Christine Wulff
Journal:  Mol Cancer       Date:  2016-02-12       Impact factor: 27.401

9.  Markers of liver regeneration-the role of growth factors and cytokines: a systematic review.

Authors:  Katrin Hoffmann; Alexander Johannes Nagel; Kazukata Tanabe; Juri Fuchs; Karolin Dehlke; Omid Ghamarnejad; Anastasia Lemekhova; Arianeb Mehrabi
Journal:  BMC Surg       Date:  2020-02-12       Impact factor: 2.102

10.  Clinical outcome, proteome kinetics and angiogenic factors in serum after thermoablation of colorectal liver metastases.

Authors:  Marieke W J L A E Wertenbroek; Marianne Schepers; Hannetta J Kamminga-Rasker; Jan T Bottema; Anneke C Muller Kobold; Han Roelofsen; Koert P de Jong
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.